A widely available and affordable blood-thinning drug, heparin, limits lung damage when inhaled by Covid-19 patients, and may also prevent infection from the SARS-CoV-2 virus, according to early results of a study. Researchers from the Australian National University (ANU) and colleagues are tracking hospital patients infected with SARS-CoV-2 in 13 countries who were given
A widely available and affordable drug, heparin, limits lung damage when inhaled by COVID-19 patients, according to world-first findings by researchers from The Australian National University (ANU).
Initial results of an Australian study indicate the drug Heparin could be “a promising treatment” and also “a possible preventative against the virus” when inhaled.
Initial results of an Australian study indicate the drug Heparin could be “a promising treatment” and also “a possible preventative against the virus” when inhaled.